MX2022013051A - Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos. - Google Patents

Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.

Info

Publication number
MX2022013051A
MX2022013051A MX2022013051A MX2022013051A MX2022013051A MX 2022013051 A MX2022013051 A MX 2022013051A MX 2022013051 A MX2022013051 A MX 2022013051A MX 2022013051 A MX2022013051 A MX 2022013051A MX 2022013051 A MX2022013051 A MX 2022013051A
Authority
MX
Mexico
Prior art keywords
heteroaromatic
chemotherapeutic agents
macrocyclic ether
macrocyclic
compounds
Prior art date
Application number
MX2022013051A
Other languages
English (en)
Inventor
Joshua Courtney Horan
Xinxing Tang
Henry Efrem Pelish
Matthew D Shair
Scot Richard Mente
Anupong Tangpeerachaikul
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of MX2022013051A publication Critical patent/MX2022013051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de éter macrocíclico heteroaromático heterocíclico, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos. También se describen métodos para tratar o prevenir el cáncer utilizando compuestos de éter macrocíclico heteroaromático heterocíclico, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos.
MX2022013051A 2020-05-05 2021-05-05 Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos. MX2022013051A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088589 2020-05-05
US202063060331P 2020-08-03 2020-08-03
US202063125747P 2020-12-15 2020-12-15
PCT/US2021/030940 WO2021226269A1 (en) 2020-05-05 2021-05-05 Heteroaromatic macrocyclic ether chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MX2022013051A true MX2022013051A (es) 2023-01-24

Family

ID=78468373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013051A MX2022013051A (es) 2020-05-05 2021-05-05 Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.

Country Status (12)

Country Link
US (2) US11667649B2 (es)
EP (1) EP4146205A4 (es)
JP (1) JP2023525040A (es)
KR (1) KR20230005987A (es)
AU (1) AU2021268345A1 (es)
BR (1) BR112022022530A2 (es)
CA (1) CA3179702A1 (es)
CL (1) CL2022003046A1 (es)
IL (1) IL297898A (es)
MX (1) MX2022013051A (es)
PE (1) PE20230309A1 (es)
WO (1) WO2021226269A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
JP2023525040A (ja) 2020-05-05 2023-06-14 ヌバレント， インク． ヘテロ芳香族大環状エーテル化学療法剤
WO2023179600A1 (zh) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
TW202400608A (zh) * 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024074414A1 (en) * 2022-10-06 2024-04-11 Syngenta Crop Protection Ag Herbicidal imidazole compounds
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US6660867B2 (en) 2000-12-20 2003-12-09 Kyowa Hakko Kogyo Co., Ltd. Metal complex type squarylium compounds and optical recording media made by using the same
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP2325225B2 (en) 2002-10-30 2019-12-11 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
SV2005002092A (es) 2004-04-27 2005-12-13 Wyeth Corp " proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos " ref. am - 101481salvo.
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
WO2009000412A1 (en) 2007-06-26 2008-12-31 Sanofi Aventis A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
AU2008272693A1 (en) 2007-07-02 2009-01-08 Astrazeneca Ab 3-spiropyrimidinetrione-quinoline derivatives and their use as antibacterial agents
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
BR112012002446B1 (pt) 2009-08-04 2017-06-27 Tokuyama Corporation Chromen compound, curable, photochemical composition, optical article, and, naftol compound.
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
IN2012DN03217A (es) 2009-09-16 2015-10-23 Cylene Pharmaceuticals Inc
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP2013532691A (ja) 2010-07-30 2013-08-19 ドクター レディズ ラボラトリーズ リミテッド 選択的非対称ヒドロホルミル化のための配位子
TW201307357A (zh) 2010-11-22 2013-02-16 Array Biopharma Inc 治療神經退化性疾病之化合物
ES2559519T3 (es) 2010-12-22 2016-02-12 Université Catholique de Louvain Nuevos derivados de fenazina y su uso
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
LT2658844T (lt) 2010-12-28 2017-02-10 Sanofi Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
US20140030529A1 (en) 2011-01-27 2014-01-30 Tokuyama Corporation Chromene compound
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
CN102977150B (zh) 2011-09-06 2016-07-06 郑建鸿 含有碳烯配位基的过渡金属错合物结构及其在发光材料的应用
AU2013229173B2 (en) * 2012-03-06 2017-06-01 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
US9502667B2 (en) 2013-01-24 2016-11-22 Idemitsu Kosan Co., Ltd. Organic electroluminescence
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
ES2656189T3 (es) 2013-06-28 2018-02-26 Pfizer Inc. Formas sólidas de un inhibidor macrocíclico de quinasa
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
WO2017081483A1 (en) 2015-11-13 2017-05-18 Mavalon Therapeutics Limited Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
EP3763693A1 (en) 2016-03-03 2021-01-13 Shenzhen TargetRx, Inc. Macrocycle and composition comprising thereof
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
US20210283261A1 (en) 2017-12-05 2021-09-16 Icahn School Of Medicine At Mount Sinai Compositions and Methods for Treating ALK-Mediated Cancer
WO2019120263A1 (zh) 2017-12-21 2019-06-27 广州华睿光电材料有限公司 有机混合物及其在有机电子器件中的应用
CN111511749B (zh) * 2018-01-30 2022-02-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
KR102233636B1 (ko) 2018-02-21 2021-03-30 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
EP3827003A1 (en) 2018-07-26 2021-06-02 Enterome Process for preparing mannose derivatives
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
AU2019348006A1 (en) 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP3844166B1 (en) 2019-05-14 2023-07-12 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
WO2021025371A1 (ko) 2019-08-02 2021-02-11 덕산네오룩스 주식회사 유기전기소자
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
EP4079740A4 (en) 2019-12-16 2023-06-07 I-Sens, Inc. NEW TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIOSENSOR USING IT
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
JP2023525040A (ja) 2020-05-05 2023-06-14 ヌバレント， インク． ヘテロ芳香族大環状エーテル化学療法剤
CN115362155A (zh) 2020-07-22 2022-11-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用

Also Published As

Publication number Publication date
EP4146205A4 (en) 2024-05-29
WO2021226269A1 (en) 2021-11-11
KR20230005987A (ko) 2023-01-10
IL297898A (en) 2023-01-01
US11667649B2 (en) 2023-06-06
EP4146205A1 (en) 2023-03-15
CL2022003046A1 (es) 2023-10-06
US20220098212A1 (en) 2022-03-31
PE20230309A1 (es) 2023-02-14
CA3179702A1 (en) 2021-11-11
AU2021268345A1 (en) 2022-11-10
US20220340586A9 (en) 2022-10-27
US20230076627A1 (en) 2023-03-09
JP2023525040A (ja) 2023-06-14
BR112022022530A2 (pt) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2022013051A (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.
MX2022013657A (es) Quimioterápicos de éter macrocíclico heteroaromático.
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
ZA202004729B (en) Pharmaceutical compounds
MX2019010988A (es) Compuestos macrociclicos como inhibidores de la quinasa ros1.
JOP20220142A1 (ar) مثبطات kras g12c
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
GEP20237560B (en) Fused pyrazine derivatives as a2a / a2b inhibitors
PH12021550124A1 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12018501920A1 (en) Bromodomain inhibitors
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2021010321A (es) Compuestos macrociclicos.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2021007247A (es) Derivados de rapamicina.